Skip to main content
OpenTrials
Completed

NCT Number: NCT03343704

This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding

The primary objective is to demonstrate reversal of the anticoagulant effect of dabigatran in patients treated with dabigatran etexilate who have uncontrolled or life-threatening bleeding requiring urgent intervention, and in patients treated with dabigatran etexilate who require emergency surgery or other invasive procedure.

The secondary objectives are to assess the reduction or cessation of bleeding, evaluate the clinical outcomes, safety and the pharmacokinetics of dabigatran in the presence of idarucizumab.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hemorrhage Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Beijing AnZhen Hospital, Beijing, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years at screening.
  • Male or female patients. Women of childbearing potential (WOCBP) and men able to father a child must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial
  • Currently taking dabigatran etexilate
  • They meet the following criteria:
  • Group A: Overt bleeding judged by the physician to require a reversal agent. OR
  • Group B: A condition requiring emergency surgery or invasive procedure where adequate hemostasis is required. Emergency is defined as within the following 8 hours.

Exclusion criteria

Group A:

  • Patients with minor bleeding (e.g. epistaxis, hematuria) who can be managed with standard supportive care.
  • Patients with no clinical signs of bleeding.
  • Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).

Group B:

  • A surgery or procedure which is elective or where the risk of uncontrolled or unmanageable bleeding is low.
  • Contraindications to study medication including known hypersensitivity to the drug or its excipients (subjects with hereditary fructose intolerance may react to sorbitol).

Treatment and study plan

idarucizumab

Drug

Intravenous

Other names: PRAXBIND, Praxbind, Prizbind

Primary outcomes

  1. Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Ecarin Clotting Time

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

    Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of ecarin clotting time is reported.

    The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is > 100, it was set to 100. 100% ULN is 41.26 seconds.

  2. Maximum Reversal of Anticoagulant Effect of Dabigatran Based on Central Laboratory Determination of Diluted Thrombin Time

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

    Maximum reversal of anticoagulant effect of dabigatran based on central laboratory determination of diluted thrombin time is reported.

    The maximum reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is > 100, it was set to 100. 100% ULN is 35.54 seconds.

Secondary outcomes

  1. Percentage of Participants Achieving Cessation of Bleeding Within 24 Hours After Completion of Second Infusion (for Group A Only)

    Time frame: Up to 24 hours after the completion of the second infusion on Day 1 of the treatment period.

    Percentage of participants achieving cessation of bleeding within 24 hours after completion of second infusion for Group A is reported.

  2. Number of Participants With Major Bleeding (for Group B Only) Intra-operatively and up to 24 Hours Post-surgery

    Time frame: Up to 24 hours post-surgery.

    Number of participants with major bleeding (for Group B only) intra-operatively and up to 24 hours post-surgery per International Society for Thrombosis and Hemostasis (ISTH) classification is reported.

  3. Minimum Unbound Sum Dabigatran Concentrations Since the End of First Infusion up to 4 Hours After the Completion of the Last Infusion (Cmin,1)

    Time frame: Just prior to the second infusion (last infusion) and 10 minutes (min), 30 min, 1 hour (h), 2 h, and 4 h after the end of the second infusion.

    Minimum unbound sum dabigatran concentrations since the end of first infusion up to 4 hours after the completion of the last infusion (Cmin,1) is reported.

  4. Maximum Reversal of Anticoagulation as Measured by Activated Partial Thromboplastin Time (aPTT)

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

    Maximum reversal of anticoagulation as measured by activated partial thromboplastin time (aPTT) is reported.

    The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If the calculated reversal is > 100, it was set to 100. 100% ULN is 39.80 seconds.

  5. Maximum Reversal of Anticoagulation as Measured by Thrombin Time (TT)

    Time frame: From the end of first infusion up to 4 hours after the completion of the second infusion on Day 1 of the treatment period.

    Maximum reversal of anticoagulation as measured by thrombin time (TT) is reported.

    The reversal of anticoagulant effect of dabigatran is defined for patients with at least one post-dose coagulation test results and pre-dose result higher than 100% Upper limit of normal (ULN). Maximum reversal is calculated as 100% x (pre-dose value - post-dose value)/(pre-dose value - 100% ULN). If calculated reversal is > 100, it was set to 100. 100% ULN is 14.22 seconds.

  6. Numbers of Participants With Any Adverse Events - on Treatment

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

    Numbers of participants with any adverse events during on treatment period is reported.

  7. Numbers of Participants With Any Adverse Events - Including Post Treatment Period

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

    Numbers of participants with any adverse events until end of study is reported.

  8. Number of Participants With Serious Adverse Events - on Treatment

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

    Number of participants with Serious adverse events during on treatment period is reported.

  9. Number of Participants With Serious Adverse Events - Including Post Treatment Period

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

    Number of participants with Serious adverse events until the end of study is reported.

  10. Number of Participants With Drug-related Adverse Events - on Treatment

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

    Numbers of patients with drug-related adverse events during on treatment period is reported.

  11. Number of Participants With Drug-related Adverse Events - Including Post Treatment Period

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

    Numbers of patients with drug-related adverse events until end of study is reported.

  12. Number of Participants With Immune Reaction Adverse Event - on Treatment

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

    Number of participants with immune reaction adverse event during on treatment period is reported.

  13. Number of Participants With Immune Reaction Adverse Event - Including Post Treatment Period

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

    Number of participants with immune reaction adverse event until end of study is reported.

  14. Number of Participants With Thrombotic Events - on Treatment

    Time frame: Since the first infusion up until 5 days after the completion of the second infusion.

    Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) during on treatment period is reported.

  15. Number of Participants With Thrombotic Events - Including Post Treatment Period

    Time frame: Since informed consent up to 30 days (± 7 days) after the completion of the second infusion, up to 37 days.

    Number of participants with thrombotic events (ischemic stroke, myocardial infarction, pulmonary embolism, deep vein thrombosis, systemic embolism) until end of study is reported.

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.

Important dates

Study start
2018
Primary completion
2020
Study completion
2020
First posted
Nov 17, 2017
Registry last updated
Feb 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.